Notes from the National Guideline Clearinghouse (NGC)
- In March 2008, the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand released an addendum to their 2006 guidelines for the management of acute coronary syndrome, highlighting evidence "that strengthens the recommendations in the guidelines or provides alternatives to current recommended practice that should be considered based on the circumstances of the individual patient and setting." This new information is presented under the heading "2008 Addendum: Implications of the Findings."
- The National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand released an additional addendum in August 2011. This addendum "summarises clinical trial evidence published since 2007 that is relevant to the recommendations contained in the Heart Foundation's Guidelines for the management of acute coronary syndromes 2006 and 2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. These recommendations are directed at the management of patients with spontaneous acute coronary syndromes, rather than those occurring as a result of other conditions (e.g., anaemia or thyrotoxicosis) where management may be directed at the underlying cause. This new information is presented under the heading "2011 Addendum."
- Definitions for the strength of recommendations and levels of evidence for the 2011 addendum are provided at the end of the "Major Recommendations" field.
The recommendations that follow are from the 2006 guideline's "Summary of Key Recommendations"; detailed graded recommendations can be found in the original guideline document.
Systems of Care for Patients with Acute Coronary Syndromes
- Effective systems of care are required to deliver optimal care for patients with acute coronary syndromes (ACS), particularly in rural and remote areas.
- Systems of care should be regionally based, and have formal links with specialist centres for consultation and acute interhospital transfer.
- Systems should include appropriate monitoring, feedback, and quality improvement components.
- Clinical decisions about care and transfer should take into account patients' cultural and personal beliefs and wishes.
New Acute Coronary Syndrome Terminology and Implications for Diagnosis
- It is important to establish an initial working diagnosis to guide clinical decision making.
- New definitions of myocardial infarction, based heavily on the presence of cardiac biomarkers, have implications for coding and epidemiological studies. However, clinically they do not influence the indications for ongoing prevention therapies.
- Use of the ACS Dataset (part of the National Health Data Dictionary) can facilitate the collection of data relating to the presentation and management of ACS that can be compared and collated within and between health care providers.
Acute Management of Chest Pain
- People experiencing symptoms of an ACS should seek help promptly and activate emergency medical services.
- The most important initial need is access to a defibrillator to avoid early cardiac death resulting from reversible arrhythmias.
- Aspirin should be given early (i.e., by emergency or ambulance personnel) unless already taken or contraindicated.
- Oxygen should be given, as well as glyceryl trinitrate and intravenous morphine as required.
- As a minimum, medical facilities receiving patients should be given warning of incoming patients in whom there is a high suspicion of an ACS—particularly ST-segment-elevation myocardial infarction (STEMI)—or whose condition is unstable.
- Where appropriate, a 12-lead electrocardiogram (ECG) should be taken en route and transmitted to a medical facility.
- Where formal protocols are in place, prehospital treatment (including fibrinolysis in appropriate cases) should be facilitated.
- The ECG is the sole test required to select patients for emergency reperfusion (fibrinolytic therapy or direct percutaneous coronary intervention [PCI]).
- Patients with STEMI who present within 12 hours of the onset of ischaemic symptoms should have a reperfusion strategy implemented promptly.
- Patients with a suspected ACS without ST-segment elevation on ECG should undergo further observation and investigation to rule out other diagnoses, enable risk stratification, and determine the most appropriate treatment strategy.
- Patients whose ECG and cardiac marker levels are normal after a suitable period of observation should, where practicable, undergo provocative testing (e.g., stress test) before discharge.
Management of Patients with ST-Segment-Elevation Myocardial Infarction
Adjuvant Therapy in Association with Reperfusion
- All patients undergoing reperfusion therapy for STEMI (PCI or fibrinolysis) should be given aspirin and clopidogrel unless these are contraindicated.
- Antithrombin therapy should be given in combination with PCI or fibrinolytic therapy with fibrin-specific fibrinolytic agents, but antithrombin therapy in conjunction with streptokinase is optional.
- It is reasonable to use abciximab with primary PCI, but glycoprotein (GP) IIb/IIIa inhibitors should generally be avoided with full or reduced doses of fibrinolytic therapy.
Choice of Reperfusion Strategy
Choice of Fibrinolytic Agent
- Second-generation fibrin-specific fibrinolytic agents that are available as a bolus (i.e., reteplase, tenecteplase) are the fibrinolytics of choice.
- These agents should be available at all centres where fibrinolysis may be required.
- Streptokinase is an inappropriate choice in Aboriginal and Torres Strait Islander patients, or in patients with previous exposure to the drug.
Transfer after STEMI
- Patients who have had STEMI should be considered for early transfer to a tertiary cardiac centre with PCI facilities and links to cardiac surgical facilities.
- If immediate transfer is not possible, patients should be transferred or referred as soon as is practicable for assessment of need for revascularisation (through PCI or coronary artery bypass grafting).
Management of Patients with Non-ST-Segment-Elevation Acute Coronary Syndromes
- All patients with non-ST-segment-elevation acute coronary syndromes (NSTEACS) should have their risk stratified to direct management decisions (see page 20 in the original guideline document for stratification criteria).
- All patients with NSTEACS should be given aspirin, unless contraindicated.
- High-risk patients with NSTEACS should be treated with aggressive medical management (including aspirin, clopidogrel, unfractionated heparin or subcutaneous enoxaparin, intravenous tirofiban or eptifibatide and a beta-blocker), and arrangements should be made for coronary angiography and revascularisation, except in those with severe comorbidities.
- Intermediate-risk patients with NSTEACS should undergo an accelerated diagnostic evaluation and further assessment to allow reclassification as low or high risk.
- Low-risk patients with NSTEACS, after an appropriate period of observation and assessment, may be discharged on upgraded medical therapy for outpatient follow up.
Long-term Management after Control of Myocardial Ischaemia
- Before discharge, patients with an ACS should be initiated on a medication regimen, including antiplatelet agent(s), beta-blocker, angiotensin-converting enzyme inhibitor, statin, and other therapies as appropriate.
- Implantable cardiac defibrillators should be considered in some patients who, despite optimal medical therapy, have persistently depressed left ventricular function more than 6 weeks after STEMI.
- Patients should be given advice on lifestyle changes that will reduce the risk of further coronary heart disease (CHD) events, including smoking cessation, nutrition, alcohol, physical activity, and weight management as relevant.
- All patients should have access to, and be actively referred to, comprehensive ongoing prevention and cardiac rehabilitation services.
- All patients should be provided with a written action plan for chest pain.
- Depression and CHD frequently coexist, and in patients with CHD, the presence of depression is more likely to lead to poorer outcomes. Social isolation and lack of social support are also associated with worse outcomes. All patients with CHD should be assessed for depression and level of social support.
2008 Addendum: Implications of the Findings
Reperfusion and Revascularisation for ST-Segment Elevation Myocardial Infarction
- The evidence for rescue PCI has strengthened since the development of the 2006 guidelines.
- Patients who receive fibrinolytic therapy and have not reperfused by 90 minutes should be considered for rescue PCI, which optimally should be performed within 12 hours. Transfer between facilities may be necessary to achieve this, and systems need to be in place to facilitate transfer of appropriate patients. If it is not possible for transfer within the 12-hour window, then transfer can be delayed if the patient is asymptomatic.
Patients in whom the infarct-related artery is completely occluded do not benefit from re-opening the artery routinely if this occurs more than 24 hours after the initial event. If patients are symptomatic, revascularisation may be considered.
Antiplatelet and Antithrombin Therapy
Recent evidence, while providing additional information on outcomes for individual agents, does not provide conclusive evidence of the superiority of one agent over another, nor of one combination of therapies over another. The risks and benefits of these therapies and strategies should be evaluated individually in each patient.
Antithrombin Therapy for Acute STEMI
Enoxaparin and fondaparinux are appropriate antithrombin agents and may be considered for use in patients with STEMI.
Antithrombin Therapy for NSTEACS
- Fondaparinux and bivalirudin, both currently not licensed for upstream therapy of NSTEACS, may be preferable alternatives to standard therapy with unfractionated heparin or low molecular weight heparin with a GP IIb/IIIa inhibitor for patients with high-risk NSTEACS, particularly where there is an increased risk of bleeding. The selection of the most appropriate upstream therapy may best be determined for any individual patient from their risk of ischaemia versus bleeding.
- Fondaparinux may be particularly useful in patients for whom invasive management is significantly delayed or those not suitable for invasive management.
- Bivalirudin has the advantage of monotherapy for both upstream and procedural administration at the time of PCI, and therefore may be particularly useful in patients planning to have an early invasive intervention.
Antiplatelet Therapy for NSTEACS
- GP IIb/IIIa inhibition with abciximab reduces adverse cardiac events in biomarker-positive NSTEACS patients undergoing PCI who have been pretreated with clopidogrel. Pretreatment with high-dose clopidogrel is not an adequate alternative to abciximab among biomarker-positive NSTEACS patients.
- A deferred in-lab initiation approach to the use of intravenous GP IIb/IIIa inhibitors (particularly with abciximab) may be preferable to short-term (median 4 hours) upstream administration in patients presenting with high-risk NSTEACS.
Investigation: Serum Troponin Measurement
Implications of the Findings
The 2006 Guidelines advised that serum troponin levels be measured on admission to the emergency department (ED). This recommendation still applies.
The 2006 Guidelines recommended that, if the initial troponin test is negative, it should be repeated at least 8 hours after the last episode of pain or other symptoms of coronary insufficiency. (When used in this way, troponin assays have a high sensitivity for detecting myocardial infarction [MI], but levels may be normal in other presentations of ACS.) This recommendation still applies when using standard-sensitivity troponin assays.
- Where available, high sensitivity troponin assays should be used in preference to conventional assays. [Grade of recommendation N/A]
- When using high sensitivity troponin assays for the identification of patients at increased risk (see Recommended protocol in the original guideline document):
- A test should be interpreted as positive if level is ≥99th centile for reference population OR there is a change of >50% above an initial baseline level. A positive finding identifies patients at increased risk, but does not provide definitive evidence of MI. A positive troponin result should be followed up by a search for an alternative plausible diagnosis and/or cardiac consultation if ACS is suspected in the context of the clinical presentation. [Consensus recommendation]
- At 3 hours after presentation, a test should be interpreted as negative if level is <99th percentile AND change from baseline is <50% (with at least one of these assays having been performed >6 hours from symptom onset). A negative test in this circumstance may be used in an "early rule-out ACS" strategy to enable earlier functional or anatomic testing for symptomatic coronary artery disease. [Grade C recommendation; Evidence level III]
- If the local pathology laboratory cannot provide troponin results within 60 min, point-of-care testing should be performed. [Grade of recommendation N/A]
Choice of Reperfusion Therapy for STEMI
Implications of the Findings
The 2006 Guidelines indicated that undertaking immediate PCI after full-dose fibrinolysis, regardless of reperfusion status (also known as facilitated PCI) could not be recommended at the time of writing.
- Consider early routine angiography and revascularisation amongst patients receiving fibrinolysis, regardless of the success of pharmacologic reperfusion. [Grade A recommendation, Evidence level I]
- Antiplatelet therapies should be continued for 12 months for all stented patients. [Grade A recommendation, Evidence level II]
- The use of mechanical thrombectomy techniques to reduce thrombus burden during primary PCI should be considered. [Grade A recommendation, Evidence level I]
Antithrombotic Therapy for STEMI
Implications of the Findings
The 2006 Guidelines recommended that:
- Antithrombin therapy with unfractionated (UF) heparin should be used in conjunction with PCI and fibrinolysis for patients with STEMI.
- It is reasonable to use abciximab with primary PCI.
- GP IIb/IIIa inhibitors should not be used with full or reduced doses of fibrinolytic therapy.
The 2007 Addendum recommended that enoxaparin and fondaparinux were appropriate antithrombin agents for use in patients with STEMI.
- Amongst patients with STEMI undergoing primary PCI, the use of bivalirudin can be considered as an alternative to heparin and GP IIb/IIIa inhibitors. [Grade B recommendation; Evidence level II]
- Amongst patients undergoing primary PCI for reperfusion for STEMI or revascularisation for ACS, a high-dose clopidogrel regimen (600 mg oral bolus and 150 mg daily for 7 days, then 75 mg/day for at least 12 months) should be considered. [Grade B recommendation, Evidence level II]
- In patients undergoing PCI, the use of an oral antiplatelet agent (prasugrel and ticagrelor) should be considered as an alternative to clopidogrel for subgroups at high risk of recurrent ischaemic events (e.g., those with diabetes, stent thrombosis, recurrent events on clopidogrel or a high burden of disease on angiography). Careful assessment of bleeding risk should be undertaken before using these agents. [Grade B recommendation; Evidence level II]
Antithrombotic Therapy for NSTEACS
Implications of the Findings
The 2006 Guidelines recommended use of heparin or subcutaneous enoxaparin until angiography, or for 48–72 hours, for those with high-risk NSTEACS.
The 2007 addendum indicated that fondaparinux and/or bivalirudin (both of which were then unlicensed for upstream therapy for NSTEACS), may be preferable alternatives to standard therapy with UF heparin or low-molecular-weight heparin (LMWH) with a GPIIb/IIIa inhibitor for patients with high-risk NSTEACS, particularly in patients with an increased risk of bleeding.
A new paradigm for the management of patients with high-risk NSTEACS is now recommended. Management decisions must take into consideration the balance between ischaemic and bleeding risk for the individual patient.
- For all patients with high-risk NSTEACS, consider methods to reduce bleeding risk. [Grade A recommendation, Evidence level I]
- Titrate antithrombotic agents to optimal dose for weight and renal function. [Grade A recommendation, Evidence level I]
- Avoid upstream GP IIb/IIIa inhibitors unless there is recurrent ischaemia on standard medical therapy. [Grade B recommendation, Evidence level II]
- Consider radial access in preference to femoral access for PCI, but be mindful that this may be used as a conduit for surgery (coronary artery bypass graft [CABG]). [Grade B recommendation, Evidence level III]
- During PCI, avoid right heart catheterisation and intra-aortic balloon pulsation unless indicated, and avoid prolonged procedure times. [Grade C recommendation, Evidence level III]
- For all patients with high-risk NSTEACS, assess bleeding risk individually according to the number and severity of bleeding risk factors (see Bleeding risk in ACS, below). [Grade A recommendation, Evidence level II]
- Assign a management strategy according to assessed individual bleeding risk:
Use a "standard" strategy for patients at low risk of bleeding:
- Choose the most effective anti-platelet regimen (e.g., prasugrel or ticagrelor). [Grade A recommendation, Evidence level I], and use fast-acting agents or multiple agents, as required, to control ischaemia rapidly. [Grade B recommendation, Evidence level II]
Use a "priority low-bleeding" strategy in patients at high risk of bleeding:
- Use antithrombotic agents with a lower bleeding risk, e.g.:
- Clopidogrel in preference to prasugrel. [Grade B recommendation, Evidence level II]
- (In the context of a non-invasive strategy) fondaparinux in preference to enoxaparin. [Grade B recommendation, Evidence level II]
- (In the context of an invasive strategy) bivalirudin in preference to enoxaparin. [Grade B recommendation, Evidence level II]
- Minimise the number of agents used. [Grade B recommendation, Evidence level II]
- When additional agents are needed, consider substituting rather than adding them. [Grade B recommendation, Evidence level II]
- Consider shorter-acting or reversible agents, e.g., bivalirudin. [Grade B recommendation, Evidence level II]
- Avoid the use of GP IIb/IIIa inhibitors, if possible. [Grade B recommendation, Evidence level II]
Bleeding Risk in ACS
Implications of the Findings
The 2006 Guidelines specify the following contraindications to fibrinolysis based on bleeding risk:
- Full-dose GP IIb/IIIa inhibitors with fibrinolytic therapy, particularly in the elderly
- Active bleeding or bleeding diathesis (excluding menses)
- Significant closed head or facial trauma within 3 months
- Suspected aortic dissection (including new neurological symptoms)
- Current use of anticoagulants (risk of bleeding is positively correlated with international normalised ratio)
- Non-compressible vascular punctures
- Recent major surgery (<3 weeks)
- Traumatic or prolonged (>10 min) cardiopulmonary resuscitation
- Recent (within 4 weeks) internal bleeding (for example, gastrointestinal or urinary tract haemorrhage)
- Active peptic ulcer
These recommendations still apply in addition to new recommendations.
- The following risk factors should be considered when assessing bleeding risk and when choosing anti-thrombotic therapies in patients with ACS [Grade B recommendation, Evidence level II]:
- Age >75 years
- Female sex
- History of bleeding
- History of stroke or transient ischaemic attack (TIA)
- Creatinine clearance rate <60 mL/min
- Heart failure
- Blood pressure <120 mmHg or >180 mmHg
- Peripheral vascular disease
- Concomitant use of a GP IIb/IIIa inhibitor
- Administration of enoxaparin 48 hours prior to intervention
- Switching between UF heparin and enoxaparin
- Procedural factors associated with increased risk (femoral artery versus radial artery access, prolonged procedure, intra-aortic balloon pulsation, right heart catheterisation)
Oxygen Therapy for Patients with ACS
Implications of the Findings
The 2006 Guidelines recommended administration of oxygen in transit and on arrival to hospital for patients with suspected ACS. This recommendation has been superseded.
- The routine use of supplemental oxygen is not recommended. [Grade C recommendation, Evidence level I]
- Oxygen therapy is indicated for patients with hypoxia (oxygen saturation <93%) and those with evidence of shock, to correct tissue hypoxia. In the absence of hypoxia, the benefit of oxygen therapy is uncertain, and in some cases oxygen therapy may be harmful. [Consensus recommendation]
Implications of the Findings
Timely reperfusion remains a key treatment objective in the management of STEMI.
The 2006 Guidelines stated that local approaches to reperfusion depend on the specific local resources available for assessment, transfer, and delivery of care.
- System-based approaches to deliver timely reperfusion should be undertaken at local level. Establishment of clinical networks and efficient protocols to maximise the proportion of patients receiving timely reperfusion should be considered. [Grade B recommendation; Evidence level III-1]
- Routine audit should be integrated into all clinical services that provide care to patients with ACS. [Grade B recommendation; Evidence level III]
- In the absence of ready access to primary PCI services, systems should be developed to train local general practitioners and other health workers to initiate fibrinolysis in patients with STEMI, to maintain practitioners' skills, and to ensure practitioners are supported by ready access to expert cardiology consultation. [Recommendation grade N/A]
2011 Addendum Grades of Recommendations
A. Body of evidence can be trusted to guide practice
B. Body of evidence can be trusted to guide practice in most situations
C. Body of evidence provides some support for recommendation(s) but care should be taken in its application
D. Body of evidence is weak and recommendation must be applied with caution
N/A. Not applicable—recommendation cannot be graded
2011 Addendum Levels of Evidence
Levels of evidence were rated according to current National Health and Medical Research Council classifications, available at the National Health and Medical Research Council Web site .
Clinical algorithms are provided in the original 2006 guideline document for the following:
- Defining acute coronary syndromes over time: presentation to final diagnosis
- Hospital management of ST-segment-elevation myocardial infarction (STEMI)
- Prehospital management of STEMI
- Treatment strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTEACS), based on risk stratification
- Implantable cardiac defibrillator (ICD) implantation after STEMI: proposed management
- Emergency department/cardiac care unit (CCU) guidelines for the management of acute coronary syndromes
An algorithm for incorporating a high sensitivity troponin into the work-up of patients with suspected acute coronary syndrome (ACS) is provided in the 2011 addendum document.
Identifying Information and Availability
|Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust. 2006 Apr 17;184(8 Suppl):S1-32. [105 references] PubMed |
|Aroney CN, Aylward P, Chew DP, Huang N, Kelly AM, White H, Wilson M, National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand. 2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. Med J Aust. 2008 Mar 3;188(5):302-3. [10 references] PubMed |
|Chew DP, Aroney CN, Aylward PE, Kelly AM, White HD, Tideman PA, Waddell J, Azadi L, Wilson AJ, Ruta LA. 2011 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ. 2011 Aug;20(8):487-502. [58 references] PubMed |
Not applicable: The guideline was not adapted from another source.
2006 Apr (addenda released 2008 Mar and 2011 Aug)
Cardiac Society of Australia and New Zealand - Disease Specific Society
National Heart Foundation of Australia - Disease Specific Society
Source(s) of Funding
National Heart Foundation of Australia
Cardiac Society of Australia and New Zealand
Acute Coronary Syndrome Guidelines Working Group
Composition of Group That Authored the Guideline
Group Members: Associate Professor Constantine N Aroney, MD, FRACP, Director, Cardiac Services, Holy Spirit Northside Hospital, Brisbane, QLD; Professor Philip Aylward, BM BCh, PhD, FRACP, FCSANZ, Director of Cardiology, Flinders Medical Centre, Adelaide, SA; Dr Roger M Allan, MB BS, FRACP, FCSANZ, FACC, Chair, Cardiac Clinical Division, Prince of Wales Hospital, Sydney, NSW; Dr Andrew N Boyden, MB BS, MPH, FRACGP, Medical Affairs Manager, National Heart Foundation of Australia, Canberra, ACT; Associate Professor David Brieger, PhD, FRACP, Cardiologist, Concord Hospital, Sydney, NSW; Dr Alex Brown, BMed, MPH, National Heart Foundation of Australia Indigenous Scholar, and Senior Research Fellow, Menzies School of Health Research, Institute of Advanced Studies, Charles Darwin University, Alice Springs, NT; Associate Professor Gerard E Carroll AM, MB BS(Hons), FRACP, Associate Professor of Medicine, University of New South Wales, Sydney, NSW, and Consultant Physician and Cardiologist, Wagga Wagga, NSW; Associate Professor Derek P B Chew, MB BS, MPH, FRACP, Cardiologist, Flinders Medical Centre and Flinders University, Adelaide, SA; Ms Eleanor Clune, BSc, GradDipSciComm, Medical Affairs Project Officer, National Heart Foundation of Australia, Melbourne, VIC; Dr Michael Flynn, MB BS, DObsRCOG, DVen, FRACGP, FAFOM, Medical Director, Ambulance Service of NSW, Sydney, NSW; Associate Professor David Hunt, MD, FRACP, Cardiologist, Royal Melbourne Hospital, Melbourne, VIC; Associate Professor Ian G Jacobs, BAppSc, DipEd, PhD, FRCNA, FACAP, RN, Chairman, Australian Resuscitation Council; Professor Anne-Maree Kelly, MD BS, MClinED, FACEM, Professor and Director, Department of Emergency Medicine, Western Hospital, Melbourne, VIC, and Director, Joseph Epstein Centre for Emergency Medicine Research, Melbourne, VIC; Mr Traven M Lea, MAE(IH), DipPHTM, National Program Manager — Aboriginal and Torres Strait Islander Program, National Heart Foundation of Australia, Brisbane, QLD; Dr Kok Shiong Tan, MB BS, FRACGP, Clinical Advisor, Department of Health, Perth, WA; Professor Andrew M Tonkin, MB BS, MD, FRACP, Chief Medical Officer, National Heart Foundation of Australia, Melbourne, VIC; Mr Tony Walker, ASM, BParamedStud, CertMICAParamedic, GradDipEd, GradCertAppMgt, Manager Operations — Clinical and Education Services, Rural Ambulance Victoria, Ballarat, VIC; Dr Warren Walsh, MB BS, FRACP, FACC, Cardiologist, Prince of Wales Hospital, Sydney, NSW; Professor Harvey White, DSc, FCSANZ, Director of Coronary Care and Cardiovascular Research, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Authors: Constantine N Aroney, MD, FRACP, Director, Cardiac Services, Holy Spirit Northside Hospital, Brisbane, QLD; Philip Aylward, PhD, FRACP, FCSANZ, Acting Director of Medicine, Flinders Medical Centre, Adelaide, SA; Derek P Chew, MBBS, MPH, FRACP, Acting Director of Cardiology, Flinders Medical Centre, Adelaide, SA, Flinders University, Adelaide, SA; Nancy Huang, MBBS, DipRACOG, MPH, National Clinical Guidelines Coordinator, National Heart Foundation of Australia, Melbourne, VIC; Anne-Maree Kelly, MDBS, MClinED, FACEM, Professor and Director, Department of Emergency Medicine, Western Hospital, Melbourne, VIC, and Director, Joseph Epstein Centre for Emergency Medicine Research, Melbourne, VIC; Harvey White, DSc, FRACP, FCSANZ, Director of Coronary Care and Cardiovascular Research, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; Michelle Wilson, BHSc, Medical Affairs Project Officer, National Heart Foundation of Australia, Melbourne, VIC
Authors: Derek P. Chew, MPH, FRACP, FACC, FCSANZ, Adelaide Health Service, Flinders Medical Centre, South Australia, Australia; Constantine N. Aroney, MD, FRACP, Holy Spirit Northside Hospital, Queensland, Australia; Philip E. Aylward, FRACP, FCANZ, FRCP, FACC, Adelaide Health Service, Flinders Medical Centre, South Australia, Australia; Anne-Maree Kelly, MClinEd, FACEM, FCCP, Joseph Epstein Centre for Emergency Medicine Research at Western Health, Sunshine Hospital, Victoria, Australia; Harvey D. White, FRACP, FACC, FESC, FAHA, FHKCC(Hon), FCSANZ, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; Philip A. Tideman, FRACP, Country Health SA, Flinders Medical Centre, South Australia, Australia; Jill Waddell, MPH, National Heart Foundation of Australia, Victoria, Australia; Leva Azadi, MPH, National Heart Foundation of Australia, Victoria, Australia; Alison J. Wilson, MBA, National Heart Foundation of Australia, Victoria, Australia; and Leah-Anne M. Ruta, PhD, National Heart Foundation of Australia, Victoria, Australia
Financial Disclosures/Conflicts of Interest
The following working group members are consultants, advisory committee members, or receive honoraria, fees for service, or travel assistance (independent of research related meetings) from, or have research or other associations with the organisations listed: Roger Allan—Merck Sharpe & Dohme, Sanofi; Con Aroney—CSL, Merck Sharpe & Dohme, Sanofi-aventis; Phil Aylward—Sanofi-aventis, Pfizer, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Procter & Gamble, Eli Lilly, The Medicines Co, Servier, CSL, Schering Plough; David Brieger—Aventis, Sanofi, Boehringer Ingelheim, Merck Sharpe & Dohme; Alex Brown—National Heart Foundation of Australia, Australian Indigenous Doctors' Association, Alice Springs Hospital Management Board, Bristol-Myers Squibb, Pfizer; Gerard Carroll—Aventis, Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Servier, Solvay, Roche; Derek Chew—Merck Sharpe & Dohme, Sanofi, Pfizer; Ian Jacobs—St John Ambulance, Australian Government Department of Health and Ageing, Convention of Ambulance Authorities Australia, National Health and Medical Research Council, Laerdal Foundation, National Heart Foundation of Australia, Health Department of Western Australia; Anne-Maree Kelly—Proctor & Gamble/Alexion, Boehringer Ingelheim; Shiong Tan—Health Department of Western Australia (Office of Safety & Quality and Sentinel event review group), Royal Australian College of General Practitioners (Quality Care National Standing Committee), National Prescribing Service (Director), Royal Australian College of General Practitioners (WA) Faculty (Director); Andrew Tonkin—AstraZeneca, Bristol-Myers Squibb, Pfizer, Sankyo, Fournier, Servier, Merck Sharpe & Dohme; Warren Walsh—Roche; Harvey White—The Medicines Company, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, Servier, Wyeth Ayerst
Constantine Aroney has received speaker fees from CSL. Philip Aylward has received research honoraria, speaker fees or travel assistance from TIMI Group (Harvard University), VIGOUR Group (Duke University), Pfizer, AstraZeneca, Eli Lilly, Boehringer Ingelheim and Sanofi-Aventis, and is a member of advisory boards to AstraZeneca, Sanofi-Aventis, Eli Lilly, CSL, Boehringer Ingelheim, and Pfizer. Derek Chew has received speaker fees from CSL and Sanofi-Aventis. Anne-Maree Kelly is a member of an advisory board to Sanofi-Aventis. Harvey White has received research grants, consulting fees or speaker fees from Sanofi-Aventis, Eli Lilly, Medicines Company, NIH, GlaxoSmithKline, Pfizer, Roche, Johnson & Johnson, Schering-Plough, Merck Sharpe & Dohme, Novartis, AstraZeneca, Boehringer Ingelheim, Servier Laboratories, Wyeth Ayerst, and Bayer
Derek Chew has received travel assistance, speaker fees or been on the advisory board for Astra Zeneca Australia, Eli-Lilly Australia and Sanofi Aventis Australia. Con Aroney has received travel assistance from Boehringer Ingelheim. Philip Aylward has received research honoraria, research grants, travel assistance or been on advisory boards for Boehringer Ingelheim, Astra Zeneca, Eli-Lilly, CSL, Merck Sharp & Dohme, Pfizer, Sanofi Aventis. Philip Tideman has received speakers honoraria from Roche Diagnostics Australia. Harvey White has received research grants from Sanofi Aventis, Eli-Lilly, The Medicines Company, National Institutes of Health, Pfizer, Roche, Johnson & Johnson, Schering Plough, Merck Sharp & Dohme, Astra Zeneca, Daiichi Sankyo Pharma Development, Bristol-Myers Squibb and consulting fees from Regado Biosciences. Anne-Maree Kelly is a member of advisory boards to Astra Zeneca and Merck Sharp & Dohme and has received travel assistance from Radiometer Pty Ltd, is the Senior Clinical Advisor for the Emergency Care Improvement and Innovation Clinical Network (Department of Health Victoria), is on the editorial boards of Emergency Medicine Australasia, Annals of Emergency Medicine and Hong Kong Journal of Emergency Medicine and conducts research in acute cardiology and biomarkers.
Australian Cardiac Rehabilitation Association - Professional Association
Australian College for Emergency Medicine - Medical Specialty Society
Australian Indigenous Doctors Association - Professional Association
Australian Resuscitation Council - Professional Association
Council of Ambulance Authorities (Australia) - Professional Association
Council of Remote Area Nurses of Australia Inc. - Professional Association
Internal Medicine Society of Australia and New Zealand - Medical Specialty Society
Kidney Health Australia - Professional Association
National Aboriginal Community Controlled Health Organisation - National Government Agency [Non-U.S.]
Royal Australian College of General Practitioners - Professional Association
Royal College of Nursing, Australia - Professional Association
This is the current release of the guideline.
Print copies: Available from the National Heart Foundation of Australia's national telephone information service at 1300 36 27 87 or E-mail: email@example.com.
Availability of Companion Documents
The following are available:
Print copies: Available from the National Heart Foundation of Australia's national telephone information service at 1300 36 27 87 or E-mail: heartlineSA@heartfoundation.com.au.
This NGC summary was completed by ECRI on April 6, 2007. The information was verified by the guideline developer on June 27, 2007. This summary was updated by ECRI Institute on March 14, 2008 following the updated FDA advisory on heparin sodium injection. This summary was updated on January 5, 2009. The updated information was verified by the guideline developer on February 2, 2009. This summary was updated by ECRI Institute on January 5, 2010 following the U.S. Food and Drug Administration advisory on Plavix (Clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This summary was updated by ECRI Institute on July 27, 2010 following the FDA drug safety communication on Heparin. This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This NGC summary was updated by ECRI Institute on March 21, 2012. The updated information was verified by the guideline developer on March 28, 2012. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins. This summary was updated by ECRI Institute on June 2, 2016 following the U.S. Food and Drug Administration advisory on Opioid pain medicines.
This NGC summary is based on the original guideline.
Copyright for the original guideline/evidence review remains with the Medical Journal of Australia. The content contained within the original guideline/evidence review may not be reproduced in any form or language without permission from the Medical Journal of Australia and the National Heart Foundation of Australia. Before applying for permissions, request for the copyright terms and conditions document from firstname.lastname@example.org. In addition, content contained within the original guideline and/or the NGC summary of this guideline may not be used for commercial and/or product endorsement.
© 2006 Australasian Medical Publishing Company Proprietary Limited